Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Understanding the Mechanism of Direct Activation of AMP-Kinase: Toward a Fine Allosteric Tuning of the Kinase Activity

  • Aledavood, E.
  • Moraes, G.
  • Lameira, J.
  • Castro Morera, Ana
  • Luque, F. Javier
  • Estarellas, Carolina
Mammalian AMP-activated protein kinase (AMPK) is a Ser/Thr protein kinase with a key role as a sensor in cellular energy homeostasis. It has a major role in numerous metabolic disorders, such as type 2 diabetes, obesity, and cancer, and hence it has gained progressive interest as a potential therapeutic target. AMPK is a heterotrimeric enzyme composed by an α-catalytic subunit and two regulatory subunits, β and γ. It is regulated by several mechanisms, including indirect activators such as metformin and direct activators such as compound A-769662. The crystal structure of AMPK bound to A-769662 has been recently reported, suggesting a hypothetical allosteric mechanism of AMPK activation assisted by phosphorylated Ser108 at the β-subunit. Here, we have studied the direct activation mechanism of A-769662 by means of molecular dynamics simulations, suggesting that the activator may act as a glue, coupling the dynamical motion of the β-subunit and the N-terminal domain of the α-subunit, and assisting the preorganization of the ATP-binding site. This is achieved through the formation of an allosteric network that connects the activator and ATP-binding sites, particularly through key interactions formed between αAsp88 and βArg83 and between βpSer108 and αLys29. Overall, these studies shed light into key mechanistic determinants of the allosteric regulation of this cellular energy sensor, and pave the way for the fine-tuning of the rational design of direct activators of this cellular energy sensor., We thank the Spanish Ministerio de Economía y Competitividad (SAF2017-88107-R, and Maria de Maetzu MDM- 2017-0767), the Generalitat de Catalunya (2017SGR1746), and Fundación Eugenio Rodríguez Pascual for financial support and the Barcelona Supercomputing Center (BSCCNS: BCV-2014-3-0011 and BCV-2019-1-0009) and the Consorci de Serveis Universitaris de Catalunya (CSUC) for providing access to computational resources. E.A. thanks AGAUR (Generalitat of Catalunya; 2018FI_B1_00001) and G.M. thanks the National Council for the Improvement of Higher Education (CAPES) for their fellowships., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

N-benzyl 4,4-disubstituted piperidines as a potent class of influenza H1N1 virus inhibitors showing a novel mechanism of hemagglutinin fusion peptide interaction

  • Castro, Sonia de
  • Ginex, Tiziana
  • Vanderlinden, E.
  • Laporte, M.
  • Stevaert, A.
  • Cumella, José
  • Gago, Federico
  • Camarasa Rius, María José
  • Luque, F. Javier
  • Naesens, L.
  • Velázquez, Sonsoles
The influenza virus hemagglutinin (HA) is an attractive target for antiviral therapy due to its essential role in mediating virus entry into the host cell. We here report the identification of a class of N-benzyl-4,4,-disubstituted piperidines as influenza A virus fusion inhibitors with specific activity against the H1N1 subtype. Using the highly efficient one-step Ugi four-component reaction, diverse library of piperidine-based analogues was synthesized and evaluated to explore the structure-activity relationships (SAR). Mechanistic studies, including resistance selection with the most active compound (2) demonstrated that it acts as an inhibitor of the low pH-induced HA-mediated membrane fusion process. Computational studies identified an as yet unrecognized fusion inhibitor binding site, which is located at the bottom of the HA stem in close proximity to the fusion peptide. A direct π-stacking interaction between the N-benzylpiperidine moiety of 2 and F9 of the fusion peptide, reinforced with an additional π-stacking interaction with Y119, and a salt bridge of the protonated piperidine nitrogen with E120, were identified as important interactions to mediate ligand binding. This site rationalized the observed SAR and provided a structural explanation for the H1N1-specific activity of our inhibitors. Furthermore, the HA-S326V mutation resulting in resistance to 2 is close to the proposed new binding pocket. Our findings point to the N-benzyl-4,4,-disubstituted piperidines as an interesting class of influenza virus inhibitors, representing the first example of fusion peptide binders with great potential for anti-influenza drug development., L.N. acknowledges the dedicated help of Talitha Boogaerts, Leentje Persoons, Wim van Dam and Ria Van Berwaer. We thank the Spanish Government (MINECO/FEDER Project SAF2015-64629- C2, SAF2017-88107: MDM-2017-0767 and AEI/FEDER UE), the Consejo Superior de Investigaciones Científicas (CSIC Project 201980E028), and the Generalitat de Catalunya (2017SGR1746) for financial support. The Barcelona Supercomputer Center (BSC) is acknowledged for providing access to supercomputation resources (BCV-2019-3-0011 and BCV-2020-1-0019
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Searching for effective antiviral small molecules against influenza A virus: A patent review

  • Ginex, Tiziana
  • Luque, F. Javier
41 p.-6 fig., Introduction Despite the current interest caused by SARS-Cov-2, influenza continues to be one of the most serious health concerns, with an estimated 1 billion cases of influenza across the globe, including 3-5 million severe cases and 290,000-650,000 deaths worldwide., Areas covered This manuscript reviews the efforts made in the development of small molecules for the treatment of influenza virus, primarily focused on patent applications in the last five years. Attention is paid to compounds targeting key functional viral proteins, such as the M2 channel, neuraminidase, and hemagglutinin, highlighting the evolution toward novel ligands and scaffolds motivated by the emergence of resistant strains. Finally, the discovery of compounds against novel viral targets, such as the RNA-dependent RNA polymerase, is discussed., Expert opinion The therapeutic potential of antiviral agents is limited by the increasing presence of resistant strains. This should encourage research on novel strategies for therapeutic intervention. In this context, the discovery of arbidol and JNJ7918 against hemagglutinin, and current efforts on RNA-dependent RNA polymerase have disclosed novel opportunities for therapeutic treatment. Future studies should attempt to expand the therapeutic arsenal of anti-flu agents, often in combined therapies, which might be relevant to prevent future health challenges caused by influenza virus., This work was supported by the Spanish Ministerio de Economia y Competitividad (MINECO, SAF2017-88107-R; MDM2017-0767; AEI/FEDER UE), and the Generalitat de Catalunya (2017SGR1746), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

HIV-1 Envelope Spike MPER: From a Vaccine Target to a New Druggable Pocket for Novel and Effective Fusion Inhibitors

  • Luque, F. Javier
  • Camarasa Rius, María José
Here we highlight a sound and unique work reported by Chen and co-workers entitled “HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes” (Xiao et al., Nat. Chem. Biol. 2020, 16, 529). In this article, the authors identify, by means of a clever antibody-guided strategy, several small molecules as fusion inhibitors of HIV-1 replication acting at the membrane proximal external region (MPER) of the HIV-1 envelope (Env) spike. MPER, which was previously recognized as a vaccine target, emerges as a novel druggable target for the discovery of HIV-1 fusion inhibitors. The compounds (exemplified by dequalinium and dequalinium-inspired analogues) prevent the conformational changes of Env from the prefusion species to the intermediate states required for membrane fusion. This work not only paves the way to novel, specific and useful anti-HIV-1 inhibitors, but also discloses new therapeutic strategies against other infectious diseases., F.J.L. and M.-J.C. thank the Spanish MINECO/FEDER (SAF2015- 64629-C2-1-R, SAF2017-88107, MDM2017-0767, AEI-FEDER UE), MICIU (PID2019-104070RB-C21) and Generalitat de Catalunya (2017SGR1746) for financial support., Peer reviewed